CareDx (CDNA) Stock Price, News & Analysis

Company Overview

CareDx, Inc. (NASDAQ: CDNA) is a precision diagnostics company focused on the care of transplant patients. The firm develops and commercializes non‐invasive tests designed to detect organ transplant rejection and infection risk, helping physicians make informed management decisions throughout the post‐transplant journey.

The company’s core product portfolio includes AlloMap®, a gene expression profiling test for heart transplant recipients, and AlloSure®, a donor‐derived cell‐free DNA assay used primarily in kidney transplant monitoring. CareDx also offers a range of clinical laboratory services and companion diagnostic solutions that support patient management in lung and liver transplantation.

Headquartered in Brisbane, California, CareDx serves transplant centers across the United States, Europe and select international markets. The company operates a network of CLIA‐certified laboratories and collaborates with academic institutions and transplant centers to advance research in immunological monitoring and personalized patient care.

CareDx was established through the integration of Viracor-IBT and Transplant Genomics in 2018, building on more than a decade of molecular diagnostic expertise. The company’s leadership team comprises seasoned professionals with backgrounds in biotechnology, laboratory operations and clinical research, all dedicated to improving outcomes for transplant recipients worldwide.

Key Stats

• Today's Range: $14.69 to $15.10
• 50-Day Range: $11.57 to $15.57
• 52-Week Range: $10.96 to $32.55
• Volume: 974,378 shs
• Average Volume: 1.32 million shs
• Market Capitalization: $787.27 million
• P/E Ratio: 14.50
• Dividend Yield: N/A
• Price Target: $25.50
• Consensus Rating: Hold

CareDx Stock Analysis - MarketRank™

CareDx scored higher than 93% of companies evaluated by MarketBeat, and ranked 70th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.2 / 5
• Analyst Rating: Hold

Consensus Rating

CareDx has received a consensus rating of Hold. The company's average rating score is 2.38, and is based on 4 buy ratings, 3 hold ratings, and 1 sell rating.

Upside Potential

CareDx has a consensus price target of $25.50, representing about 72.4% upside from its current price of $14.79.

Amount of Analyst Coverage

CareDx has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for CareDx are expected to grow in the coming year, from ($0.90) to ($0.41) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of CareDx is 14.50, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 234.02.

Price to Earnings Ratio vs. Sector

The P/E ratio of CareDx is 14.50, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 85.47.

Price to Book Value per Share Ratio

CareDx has a P/B Ratio of 2.09. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

12.90% of the float of CareDx has been sold short.

Short Interest Ratio / Days to Cover

CareDx has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in CareDx has recently decreased by 6.09%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

CareDx does not currently pay a dividend.

Dividend Growth

CareDx does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.2 / 5
• Environmental Score: -0.66

Percentage of Shares Shorted

12.90% of the float of CareDx has been sold short.

Short Interest Ratio / Days to Cover

CareDx has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in CareDx has recently decreased by 6.09%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.2 / 5
• News Sentiment: 0.77

News Sentiment

CareDx has a news sentiment score of 0.77. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.63 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for CareDx this week, compared to 6 articles on an average week.

Search Interest

4 people have searched for CDNA on MarketBeat in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, CareDx insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 4.40% of the stock of CareDx is held by insiders.

CDNA Stock Analysis - Frequently Asked Questions

How have CDNA shares performed this year?

CareDx's stock was trading at $21.41 at the beginning of the year. Since then, CDNA stock has decreased by 30.9% and is now trading at $14.79.

How were CareDx's earnings last quarter?

CareDx, Inc. (NASDAQ:CDNA) released its quarterly earnings results on Wednesday, August, 6th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.12 by $0.28. The business's revenue for the quarter was down 6.1% on a year-over-year basis.
Read the conference call transcript.

How do I buy shares of CareDx?

Shares of CDNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of CareDx own?

Based on aggregate information from My MarketBeat watchlists, some other companies that CareDx investors own include Tesla (TSLA), NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Netflix (NFLX), JPMorgan Chase & Co. (JPM) and Home Depot (HD).

Company Calendar

• Last Earnings: 8/06/2025
• Today: 10/08/2025
• Next Earnings (Estimated): 11/03/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Medical Services
• Sub-Industry: Healthcare
• Current Symbol: NASDAQ:CDNA
• CIK: 1217234
• Web: www.caredxinc.com
• Phone: (415) 287-2300
• Fax: 415-287-2450
• Employees: 740
• Year Founded: 2000

Price Target and Rating

• Average Price Target for CareDx: $25.50
• High Price Target: $40.00
• Low Price Target: $14.00
• Potential Upside/Downside: +72.4%
• Consensus Rating: Hold
• Rating Score (0-4): 2.38
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): $1.02
• Trailing P/E Ratio: 14.50
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $52.55 million
• Net Margins: 17.97%
• Pretax Margin: 17.15%
• Return on Equity: 18.03%
• Return on Assets: 12.88%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.30
• Quick Ratio: 3.00

Sales & Book Value

• Annual Sales: $333.79 million
• Price / Sales: 2.36
• Cash Flow: $1.34 per share
• Price / Cash Flow: 11.00
• Book Value: $7.06 per share
• Price / Book: 2.09

Miscellaneous

• Outstanding Shares: 53,230,000
• Free Float: 50,885,000
• Market Cap: $787.27 million
• Optionable: Optionable
• Beta: 2.37